H.C. Wainwright analyst Ed Acre raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $400.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Madrigal Pharmaceuticals (MDGL) PT Raised to $443 at Citizens JMP February 27, 2025 4:26 AM TD Cowen Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL), PT $390February 26, 2025 3:55 PM Madrigal Pharmaceuticals (MDGL) PT Raised to $469 at CitiFebruary 26, 2025 3:52 PM Madrigal Pharma (MDGL) Tops Q4 EPS by $1.77, Beats on RevenueFebruary 26, 2025 7:05 AM Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with CompeFebruary 26, 2025 7:00 AM Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASHFebruary 26, 2025 6:30 AM